Advertisement

Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD

Published on: 

Peter Libby, MD, discusses the neutral ZEUS trial and how coronary inflammation imaging could guide anti-inflammatory therapy in atherosclerosis.

For more than a decade, systemic inflammatory biomarkers have guided enrollment in anti-inflammatory cardiovascular trials, with an hs-CRP of 2 mg/L or higher as the entry threshold for JUPITER and CANTOS. The neutral results of the phase 3 ZEUS trial of ziltivekimab, an interleukin-6 (IL-6) inhibitor, have called into question how reliably lowering a biomarker translates into fewer events. The findings have renewed interest in local measures of coronary inflammation, including artificial intelligence (AI)-based analysis of coronary CT angiography.

Peter Libby, MD, of Brigham and Women’s Hospital and Harvard Medical School, discussed the implications of ZEUS with HCPLive at the American Heart Association (AHA) Scientific Sessions 2026. He also addressed whether coronary inflammation could become a clinically actionable imaging phenotype, similar to coronary artery calcium (CAC) scoring.

Why Did IL-6 Inhibition Fail to Reduce Cardiovascular Events in ZEUS?

Libby described the ZEUS results, first announced in summer 2026, as an upheaval for the field. The trial tested ziltivekimab, a monoclonal antibody targeting IL-6, a cytokine downstream of the interleukin-1β (IL-1β) target inhibited by canakinumab in CANTOS.²

ZEUS randomized 6,376 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and hs-CRP of 2 mg/L or higher to ziltivekimab 15 mg monthly or placebo.¹ The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Over a median follow-up of 33 months, the primary endpoint occurred in 17.6% (561/3,184) of patients receiving ziltivekimab and 17.7% (565/3,192) of those receiving placebo (HR, 0.99; 95% CI, 0.88–1.11; P = .84).¹

At 24 months, ziltivekimab had reduced free IL-6 by 76 percentage points and hs-CRP by 64 percentage points compared with placebo.¹ Serious infections occurred in 20.4% of the ziltivekimab group vs 17.9% of the placebo group.¹

“So there was discordance between the biomarkers and the clinical efficacy,” Libby said.

Libby suggested the trial population may partly explain the null result. ZEUS enrolled patients with considerably more advanced CKD than CANTOS did, which raises the question of whether advanced atherosclerosis in a secondary prevention population responds less to treatment. He said the IL-6 pathway may still be worth pursuing in patients with less advanced, potentially more mutable disease.

Can Coronary Inflammation Become an Imaging Phenotype Like CAC Scoring?

Libby called CAC scoring one of the best biomarkers of future cardiovascular risk, but he identified two limitations to its use as a serial measure. First, statins and extreme exercise can increase CAC scores while reducing cardiovascular events. He compared this mismatch between imaging change and outcomes to the discordance seen in ZEUS.

Second, calcified plaques mark overall disease burden but may not be the lesions causing thrombotic complications. Libby pointed instead to low-attenuation noncalcified plaques as likely culprits behind acute events.

As an alternative, Libby highlighted AI-based analysis of the perivascular fat surrounding the coronary arteries, which changes in response to inflammation within the artery wall. The fat attenuation index (FAI) score, generated by Caristo Diagnostics’ CaRi-Heart platform, received De Novo authorization from the US Food and Drug Administration (FDA) in July 2026.³ The platform quantifies coronary inflammation from routine coronary CT angiography.³

How Might the FAI Score Guide Anti-Inflammatory Therapy?

According to Libby, local coronary inflammation may capture residual inflammatory risk even when hs-CRP falls in the lower range. A patient can have substantial coronary inflammation on imaging and still fall below the hs-CRP threshold used for trial enrollment.

“You can have a high FAI score, but low CRP,” Libby said.

As an investigator in this area, Libby said he wants to see whether the FAI score works as an enrollment criterion for anti-inflammatory trials, over and above hs-CRP. He noted hs-CRP-based enrollment succeeded in JUPITER and CANTOS but not in ZEUS.

The ultimate goal, he said, would be to use changes in the FAI score as a high-fidelity predictor of cardiovascular events. Libby called this application speculative and emphasized it will need rigorous validation, as with any biomarker.

References:
  1. Ridker PM, Lincoff AM, Marx N, et al. Interleukin-6 inhibition with ziltivekimab for atherosclerotic disease. N Engl J Med. Published online November 7, 2026. doi:10.1056/NEJMoa2612126
  2. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
  3. Caristo Diagnostics’ CaRi-Heart coronary inflammation technology receives FDA De Novo authorization. Cardiac Interventions Today. Published July 30, 2026. Accessed November 17, 2026. https://citoday.com/news/caristo-diagnostics-cari-heart-coronary-inflammation-technology-receives-FDA-De-Novo-Authorization

Advertisement
Advertisement